Literature DB >> 14623022

GB virus type C/hepatitis G virus: a non-pathogenic flavivirus associated with prolonged survival in HIV-infected individuals.

Philip M Polgreen1, Jinhua Xiang, Qing Chang, Jack T Stapleton.   

Abstract

GB virus C (GBV-C) is a common virus that does not appear to cause disease. GBV-C persists in up to 50% of exposed individuals, and virus replication appears to be in lymphocytes including CD4+ T cells. GBV-C infection is common among HIV-positive people, and several studies have found that HIV-positive individuals co-infected with GBV-C survive for statistically significantly longer periods of time than people without GBV-C. In vitro studies suggest that GBV-C inhibits HIV replication and alters cytokine, chemokine and chemokine receptor expression. Thus, GBV-C may be a major factor influencing the natural history of HIV disease.

Entities:  

Mesh:

Year:  2003        PMID: 14623022     DOI: 10.1016/j.micinf.2003.08.006

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  21 in total

Review 1.  GB virus type C: a beneficial infection?

Authors:  Jack T Stapleton; Carolyn F Williams; Jinhua Xiang
Journal:  J Clin Microbiol       Date:  2004-09       Impact factor: 5.948

Review 2.  Resistance to HIV infection.

Authors:  M Marmor; K Hertzmark; S M Thomas; P N Halkitis; M Vogler
Journal:  J Urban Health       Date:  2006-01       Impact factor: 3.671

3.  GBV-C infection and risk of NHL among U.S. adults.

Authors:  Cindy M Chang; Jack T Stapleton; Donna Klinzman; James H McLinden; Mark P Purdue; Hormuzd A Katki; Eric A Engels
Journal:  Cancer Res       Date:  2014-08-12       Impact factor: 12.701

Review 4.  Role of GB virus C in modulating HIV disease.

Authors:  Carolynne Schwarze-Zander; Jason T Blackard; Juergen K Rockstroh
Journal:  Expert Rev Anti Infect Ther       Date:  2012-05       Impact factor: 5.091

5.  Deep sequencing identifies two genotypes and high viral genetic diversity of human pegivirus (GB virus C) in rural Ugandan patients.

Authors:  Ria R Ghai; Samuel D Sibley; Michael Lauck; Jorge M Dinis; Adam L Bailey; Colin A Chapman; Patrick Omeja; Thomas C Friedrich; David H O'Connor; Tony L Goldberg
Journal:  J Gen Virol       Date:  2013-09-28       Impact factor: 3.891

6.  Characterization of an immunodominant antigenic site on GB virus C glycoprotein E2 that is involved in cell binding.

Authors:  James H McLinden; Thomas M Kaufman; Jinhua Xiang; Qing Chang; Donna Klinzman; Alfred M Engel; Georg Hess; Urban Schmidt; Michael Houghton; Jack T Stapleton
Journal:  J Virol       Date:  2006-10-11       Impact factor: 5.103

7.  Effect of primer selection on estimates of GB virus C (GBV-C) prevalence and response to antiretroviral therapy for optimal testing for GBV-C viremia.

Authors:  I E Souza; J B Allen; J Xiang; D Klinzman; R Diaz; S Zhang; K Chaloner; D Zdunek; G Hess; C F Williams; L Benning; J T Stapleton
Journal:  J Clin Microbiol       Date:  2006-09       Impact factor: 5.948

8.  Contrasting roles for TLR ligands in HIV-1 pathogenesis.

Authors:  Beda Brichacek; Christophe Vanpouille; Yana Kiselyeva; Angelique Biancotto; Melanie Merbah; Ivan Hirsch; Andrea Lisco; Jean Charles Grivel; Leonid Margolis
Journal:  PLoS One       Date:  2010-09-20       Impact factor: 3.240

9.  Chimpanzee GB virus C and GB virus A E2 envelope glycoproteins contain a peptide motif that inhibits human immunodeficiency virus type 1 replication in human CD4⁺ T-cells.

Authors:  James H McLinden; Jack T Stapleton; Donna Klinzman; Krishna K Murthy; Qing Chang; Thomas M Kaufman; Nirjal Bhattarai; Jinhua Xiang
Journal:  J Gen Virol       Date:  2013-01-03       Impact factor: 3.891

10.  Role of GB virus C in HIV-1-infected and hepatitis C virus-infected hemophiliac children and adolescents.

Authors:  Solveig Tenckhoff; Thorsten Kaiser; Fritz Bredeek; Sharyne Donfield; Erika Menius; Alice Lail; Joachim Mössner; Eric S Daar; Hans L Tillmann
Journal:  J Acquir Immune Defic Syndr       Date:  2012-10-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.